Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Three-Plant FDA Warning Spooks Dr Reddy's, Clouds ANDAs

This article was originally published in Scrip

Executive Summary

Dr Reddy's Laboratories was bludgeoned on Indian bourses after the firm said that it had received FDA warning letters at three manufacturing sites, including an oncology plant, in India.


Related Content

Keeping Track: US FDA Approves Siliq, Accepts Mylan/Biocon Pegfilgrastim Biosimilar
Dr Reddy's Proprietary Products Gain US Traction Amid Tough Q2
Dr Reddy's Slumps In Q1 But Will Pressures Ease Soon?
Dr Reddy's Pumps Complex Generics Play with Teva deal


Related Companies